Zoar files Form F-4 for Impact Biomedical business combination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
September 16, 2026 9:25 AM EDTROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (DSS or the Company) today announced that Zoar Limited (Zoar or PubCo) has filed a Registration Statement on Form F-4 (the Registration Statement) with the U.S. Securities and Exchange Commission (SEC) in connection with the previously announced proposed business combination (the Business Combination) involving Impact Biomedical Inc. (NYSE American: IBO) (Impact), Zoar and certain related parties.
DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impacts proposed Business Combination with Zoar.
... More